| Literature DB >> 19493331 |
David Spoerl1, Diego Bär, Julian Cooper, Thomas Vogt, Alan Tyndall, Ulrich A Walker.
Abstract
We report a patient who presented with inflammatory back pain due to multisegmental spondylitis. Following a vertebral biopsy which failed to detect an infectious organism, the patient was treated with etanercept, a tumor necrosis factor (TNF)-alpha inhibitor, for suspected undifferentiated spondyloarthritis. The back pain worsened and the spondylitic lesions increased. Only in a vertebral rebiopsy with polymerase chain reaction (PCR) amplification of Tropheryma whipplei, the causative agent of Whipple's disease was identified. Tropheryma whipplei should be considered as a cause of spondylitis even with multisegmental involvement and in the absence of gastrointestinal symptoms. In this clinical setting, routine PCR for Tropheryma whipplei from vertebral biopsies is recommended.Entities:
Mesh:
Year: 2009 PMID: 19493331 PMCID: PMC2697142 DOI: 10.1186/1750-1172-4-13
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Figure 1MRI alterations during follow-up. Contrast-enhanced, T1 weighted, fat saturated MRI demonstrating progression of two spondylitic lesions with the onset of clear erosions in the L1/L2 segment during treatment with etanercept, a TNF-α blocking agent between years 2002 and 2005. After cessation of the TNF-α blocker and initiation of antibiotic treatment, the multisegmental spondylitis regressed (year 2006).